immunitybio.com - IBRX Income before deduction of interest, taxes and amortization

Graphic logo of ImmunityBio Inc (IBRX)

Amidst a fierce confrontation with global pharma behemoths, ImmunityBio, Inc. (IBRX) is fighting for leadership in cancer immunotherapy. Absolute operating income before depreciation allows for the filtering of market noise, with the current value standing at 0.00. Precise cold-chain logistics for the drugs ensure profit stability. The company is currently focusing on the launch of its first commercial product, eschewing merger deals in favor of expanding distribution.

Profit before payment of interest, taxes and amortization: ImmunityBio, Inc. (IBRX) for 11/23/2025 - 11/10/2026

ImmunityBio - analytical breakdowns and key metrics (IBRX)

- market value and analyst target forecast:
Market Price NantKwest|IBRX - Consensus Target
- issuer market value details:
Market Value ImmunityBio|IBRX - Enterprise Value
- book capitalization information:
Net Assets per Share ImmunityBio|IBRX - Company Book Value|Market Cap to Net Assets Ratio immunitybio.com|IBRX - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio ImmunityBio, Inc.|IBRX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital ImmunityBio Inc|IBRX - Company Debts|Debt to Book Value Ratio ImmunityBio|IBRX - Company Long-Term Debt|Short-Term Debt ImmunityBio|Critical Liquidity immunitybio.com
- company profitability and valuation multiples indicators:
IBRX - Net Income|Future Net Profit ImmunityBio, Inc.|IBRX - P/E Multiple|Future Price to Earnings Multiple immunitybio.com|IBRX - PEG Multiple|Company Value to EBITDA ImmunityBio|IBRX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year ImmunityBio|IBRX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth immunitybio.com|IBRX - Earnings per share growth in current year|Net earnings per share change forecast for next year ImmunityBio, Inc.
Analysis of all company metrics:NantKwest - IBRX
Mass-produced product of ImmunityBio

This indicator serves as a key filter during asset stress testing, allowing for an assessment of the business's actual ability to generate cash regardless of accounting depreciation. An analysis of operating income before taxes and depreciation demonstrates the commercialization efficiency of the bladder cancer therapy from ImmunityBio, Inc. (IBRX), where an upward trend would confirm successful distribution scaling and a reduced reliance on external financing.

Competitors of ImmunityBio, Inc. (IBRX)

Immunocore Corp (IMCR) - Profit before interest, taxes and amortization|JANX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RCUS (arcusbio.com)|ZYME: Operating profit EBITDA|TNGX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Iovance|Operating profit before deduction of amortization Immatics Biotechnologies (IMTX)|Profit before payment of interest, taxes and amortization Xencor, Inc. (XNCR)|Operating profit before deduction of amortization compasstherapeutics.com CMPX|Replimune - Operating profit before deduction of amortization|Operating profit EBITDA Lyell LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology, Inc.) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|Gritstone Bio - Operating profit EBITDA|Operating income before deduction of amortization kinetabio.com KA|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Turnstone Biologics Corp.|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before deduction of amortization Harpoon Therapeutics Corp (HARP)